Sovatelitide
As of the edition of 20 October 2026, Sovatelitide is a protein: in active development; acts on EDNRB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Protein
- Registered trials
- 10, 2 stopped early
- Disease areas
- Nervous system; Heart and blood vessels; Cancer; Digestive system; Inherited and neonatal; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Sovatelitide.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EDNRB | Endothelin receptor type B | P24530 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 6 | 2 | 2 | 2 |
| Phase 3 | 2 | 1 | 1 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Zydus Worldwide DMCC | Lead sponsor of trials | 2008 to now |
| Pharmazz | Lead sponsor of trials | 2018 to now |